Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Lenalidomide plus dexamethasone is superior to placebo plus DexamethAsone in patients with relapsed or refractory multiple myeloma.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma, and led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies.
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
- Jennifer N Brudno, I. Maric, J. Kochenderfer
- Medicine, BiologyJournal of Clinical Oncology
- 29 May 2018
CAR-BCMA T cells had substantial activity against heavily treated relapsed/refractory MM and should encourage additional development of CAR T-cell therapies for MM.
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit.
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
Multivariate analysis identified performance status ≥2 and bone marrow involvement as independent adverse prognostic factors for EFS and OS and further research is needed to identify predictive and/or targetable biological markers and novel therapeutic approaches for DHL patients.
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
The first-in-humans clinical trial of chimeric antigen receptor (CAR) T cells targeting BCMA demonstrates antimyeloma activity of CAR-BCMA T cells.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cells lymphomas and in combination with other cytotoxic or biologic agents.